Literature DB >> 30640465

Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.

James S Scott, Andrew Bailey, David Buttar, Rodrigo J Carbajo, Jon Curwen, Paul R J Davey, Robert D M Davies, Sébastien L Degorce, Craig Donald, Eric Gangl1, Ryan Greenwood, Sam D Groombridge, Tony Johnson, Scott Lamont, Mandy Lawson, Andrew Lister, Christopher J Morrow, Thomas A Moss, Jennifer H Pink, Radoslaw Polanski.   

Abstract

Herein, we report the identification and synthesis of a series of tricyclic indazoles as a novel class of selective estrogen receptor degrader antagonists. Replacement of a phenol, present in our previously reported tetrahydroisoquinoline scaffold, with an indazole group led to the removal of a reactive metabolite signal in an in vitro glutathione trapping assay. Further optimization, guided by X-ray crystal structures and NMR conformational work, varied the alkyl side chain and pendant aryl group and resulted in compounds with low turnover in human hepatocytes and enhanced chemical stability. Compound 9 was profiled as a representative of the series in terms of pharmacology and demonstrated the desired estrogen receptor α degrader-antagonist profile and demonstrated activity in a xenograft model of breast cancer.

Entities:  

Year:  2019        PMID: 30640465     DOI: 10.1021/acs.jmedchem.8b01837

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.

Authors:  Jun Liang; Robert Blake; Jae Chang; Lori S Friedman; Simon Goodacre; Steven Hartman; Ellen Rei Ingalla; James R Kiefer; Tracy Kleinheinz; Sharada Labadie; Jun Li; Kwong Wah Lai; Jiangpeng Liao; Vidhi Mody; Neville McLean; Ciara Metcalfe; Michelle Nannini; Daniel Otwine; Yingqing Ran; Nick Ray; Fabien Roussel; Amy Sambrone; Deepak Sampath; Maia Vinogradova; John Wai; Tao Wang; Kuen Yeap; Amy Young; Jason Zbieg; Birong Zhang; Xiaoping Zheng; Yu Zhong; Xiaojing Wang
Journal:  ACS Med Chem Lett       Date:  2020-05-26       Impact factor: 4.345

Review 2.  Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer.

Authors:  Nitish Kumar; Harmandeep Kaur Gulati; Aakriti Sharma; Shilpa Heer; Anupmjot Kaur Jassal; Lovenish Arora; Simranpreet Kaur; Atamjit Singh; Kavita Bhagat; Arshmeet Kaur; Harbinder Singh; Jatinder Vir Singh; Preet Mohinder Singh Bedi
Journal:  Mol Divers       Date:  2020-09-04       Impact factor: 2.943

Review 3.  Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.

Authors:  Irshad Ahmad; Shimy Mathew; Sofia Rahman
Journal:  RSC Med Chem       Date:  2020-03-06

4.  Stereodivergent synthesis of enantioenriched azepino[3,4,5-cd]-indoles via cooperative Cu/Ir-catalyzed asymmetric allylic alkylation and intramolecular Friedel-Crafts reaction.

Authors:  Lu Xiao; Bo Li; Fan Xiao; Cong Fu; Liang Wei; Yanfeng Dang; Xiu-Qin Dong; Chun-Jiang Wang
Journal:  Chem Sci       Date:  2022-03-30       Impact factor: 9.969

5.  Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry.

Authors:  James S Scott; Jason Breed; Rodrigo J Carbajo; Paul R Davey; Ryan Greenwood; Hoan K Huynh; Teresa Klinowska; Christopher J Morrow; Thomas A Moss; Radoslaw Polanski; J Willem M Nissink; Jeffrey Varnes; Bin Yang
Journal:  ACS Med Chem Lett       Date:  2019-09-23       Impact factor: 4.345

6.  Lipophilicity trends upon fluorination of isopropyl, cyclopropyl and 3-oxetanyl groups.

Authors:  Benjamin Jeffries; Zhong Wang; Robert I Troup; Anaïs Goupille; Jean-Yves Le Questel; Charlene Fallan; James S Scott; Elisabetta Chiarparin; Jérôme Graton; Bruno Linclau
Journal:  Beilstein J Org Chem       Date:  2020-09-02       Impact factor: 2.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.